Any process that stops, prevents, or reduces the frequency, rate or extent of immature T cell proliferation in the thymus.

Any process that stops, prevents, or reduces the frequency, rate or extent of immature T cell proliferation.

Any process that modulates the frequency, rate or extent of immature T cell proliferation in the thymus.

Any process that modulates the frequency, rate or extent of immature T cell proliferation.

The expansion of an immature T cell population by cell division in the thymus.

The expansion of an immature T cell population by cell division.

Any process that modulates the frequency, rate or extent of extrathymic T cell differentiation.

Any process that stops, prevents, or reduces the frequency, rate or extent of extrathymic T cell differentiation.

The appearance of interferon-tau due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.

The appearance of interferon-omega due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels.

Any process in which a protein is maintained in a specific location in a mitochondrion, and is prevented from moving elsewhere.

The process in which a precursor cell type acquires the specialized features of a T cell via a differentiation pathway independent of the thymus.

The chemical reactions and pathways involving vancomycin, (3S,6R,7R,11R,23S,26S,30aS,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-(N-methyl-D-leucyl)-2,5,24,38,39-pentaoxo-1H,22H-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-di(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, a complex glycopeptide from Streptomyces orientalis that inhibits a specific step in the synthesis of the peptidoglycan layer in Gram-positive bacteria.

The chemical reactions and pathways leading to the formation of ansamycins, any of a group of complex macrolactam compounds characterized by a cyclic structure in which an aliphatic ansa chain forms a bridge between two non-adjacent positions of a cyclic p-system; many exhibit antibacterial, antifungal or antitumor activity.

The chemical reactions and pathways leading to the formation of vancomycin, (3S,6R,7R,11R,23S,26S,30aS,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-(N-methyl-D-leucyl)-2,5,24,38,39-pentaoxo-1H,22H-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-di(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid, a complex glycopeptide from Streptomyces orientalis that inhibits a specific step in the synthesis of the peptidoglycan layer in Gram-positive bacteria.